Over the past 15 years, Fujifilm has invested over $10 billion through expansions and acquisitions to build its end-to-end life sciences capabilities to create an accelerated path toward greater patient access for advanced care. "Under the 'Partners for Life' umbrella, our Life Sciences Group companies offer complete solutions to the pharmaceutical and biotechnology markets, aligning with both our strategic growth plans and commitment to innovation," commented Toshihisa Iida, Director, Corporate Vice President, General Manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation, Japan. "By redefining our Life Sciences Group, we also support Fujifilm's growth strategy for the life sciences sector, where we believe that unifying under a single banner will simplify engagement for our global network of customers across the entire product development and biomanufacturing spectrum.